Pozen Inc. (POZN)

[surf1944]

7:32AM POZEN misses by $0.02, misses on revs (POZN) 4.53 : Reports Q2 (Jun) loss of $0.21 per share, $0.02 worse than the Capital IQ Consensus Estimate of ($0.19); revenues fell 83.7% year/year to $4.6 mln vs the $5.4 mln consensus. During 2011, co plans to continue the late-stage clinical development of PA32540, along with its pre-commercialization activities. Additionally, co expects that patent litigation costs will be substantially less than the $9.4 mln spent in 2010. Given that the final verdict on the Treximet patent litigation has not been issued, and the VIMOVO launch is still in its early stages, the co pany will not provide annual financial guidance at this time. At June 30, 2011, cash, cash equivalents and short-term investments totaled $52.6 mln compared to $64.1 mln at December 31, 2010